Thybon

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Thybon

Property Description
Active ingredient Tibolone
Form Oral tablet
Pharmacological class Selective Tissue Estrogenic Activity Regulator (STEAR)
Common use Management of oestrogen deficiency symptoms
Origin Synthetic steroid

What Type of Hormone Replacement Therapy (HRT) is Thybon?

Thybon is a trade name for a synthetic steroid hormone whose active substance is Tibolone. It is classified as a highly specialized Hormone Replacement Therapy (HRT) agent, distinct from conventional estrogen-progestogen combinations. Tibolone's primary classification is as a Selective Tissue Estrogenic Activity Regulator (STEAR). This designation is clinically recognized because the drug functions as a single product that yields tri-hormonal effects (estrogenic activity, progestogenic activity, and androgenic activity) via its active metabolites. The medicine is primarily positioned for use in postmenopausal women experiencing surgical or natural menopause.

Composition and General Purpose of the Tibolone Tablet

The medicinal product is consistently presented as an oral tablet for oral administration, with its core composition built around the active ingredient Tibolone and common solid pharmaceutical excipients. This standardized dosage form ensures reliable systemic delivery. The general therapeutic goal of this medication is the comprehensive management of the key consequences of oestrogen deficiency symptoms. Tibolone is used for the relief of common climacteric symptoms, such as severe hot flashes and night sweats. A key differentiating factor is its use in addressing the long-term goal of supporting the preservation of bone density, making it an option for postmenopausal women seeking relief from acute symptoms alongside preventative bone care.

Regulatory References

  1. Tibolone for postmenopausal women: systematic review of randomized trials - NIH

What side effects are possible with Thybon?

Possible Side Effects and Safety Information

The official safety profile for Tibolone (Thybon) is structured by classifying documented adverse reactions based on frequency and affected system-organ classes, distinguishing between common, non-serious effects and serious major risks as defined by regulatory authorities.


Adverse Reaction Classification

Side effects are primarily categorized into Common (occurring in ge 1/100 to < 1/10 patients) and Uncommon (ge 1/1,000 to < 1/100). Common reactions typically involve the Reproductive System and Breast Disorders, such as lower abdominal pain, vaginal discharge, endometrial thickening, and breast tenderness. Other common events are related to Metabolism (e.g., weight increase) and Skin and Subcutaneous Tissue Disorders (e.g., abnormal hair growth or acne).


Serious Documented Risks

Official regulatory documentation identifies an increased risk of specific serious conditions associated with the medicine, which include: Stroke (mostly ischemic), Venous Thromboembolism (VTE), Endometrial Cancer in women with an intact uterus, and Breast Cancer. For both Endometrial and Breast Cancer, the risk is officially documented as increasing with the duration of use of the medicine.


Safety Considerations and Restrictions

The safety profile includes time-related patterns, such as break-through bleeding or spotting possibly occurring during the initial months of treatment. The medicine is contraindicated (officially prohibited from use) in individuals with specific pre-existing conditions, including acute liver disease, undiagnosed abnormal genital bleeding, untreated endometrial hyperplasia, and known thrombophilic disorders.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile for Thybon (Tibolone) by documenting expected clinical manifestations and mandating specific emergency actions.

Documented Manifestations and Severity

Classification Official Regulatory Statement
Documented Manifestations Symptoms following acute overdosage may include gastrointestinal complaints such as nausea and vomiting. Vaginal bleeding in postmenopausal women is also specifically documented [EMA SmPC].
Expected Severity Regulatory labeling states that severe toxic effects are not expected following an acute ingestion of a high dose [FDA Prescribing Information].

Required Emergency Actions

Since no specific antidote is known for Tibolone, the management of overdose is symptomatic and supportive. Regulatory guidance requires individuals to seek immediate medical attention following any suspected overdosage or accidental high-dose ingestion [National Regulatory Authority Labeling]. Supportive procedures such as gastric lavage may be considered by medical professionals, particularly within the first few hours following ingestion, to mitigate absorption.

Summary

The official overdose profile indicates a low expected severity but mandates urgent medical assessment to ensure stability and to initiate regulator-defined symptomatic and supportive treatment. The manifestation of vaginal bleeding is a key sign documented for postmenopausal women in this context.

Therapeutic Uses of Thybon

What Thybon Treats: Main Uses and Benefits

Thybon is commonly used in situations involving certain distressing symptoms related to systemic imbalance, symptoms that may appear suddenly or fluctuate. This medicine provides supportive relief that helps ease the overall symptom burden associated with acute or disruptive episodes.

In clinical contexts, Thybon is applied across domains where additional symptomatic support is needed. It is relevant in conditions involving recurrent or episodic manifestations where symptoms present with systemic or localized discomfort. The medicine is relevant when supportive symptom management is appropriate across domains where symptoms present with systemic or localized discomfort.

It is often applied during phases when groups of symptoms create noticeable interference with daily functioning. It contributes to improved day-to-day comfort and assists with maintaining functional stability during episodes of heightened discomfort. This application may help maintain a sense of stability when symptoms are more noticeable.


Quick Fact: Support for Symptom Clusters Thybon supports the management of symptoms that cluster into patterns requiring supportive assistance, particularly when they lead to temporary physiological strain.

Regulatory References

  1. NIH MedlinePlus overview of Liothyronine

Eligibility and Restrictions for Use

Thybon (liothyronine sodium) is officially indicated for patients of any age who require replacement or supplemental therapy for hypothyroidism of various etiologies (primary, secondary, or tertiary). This includes use throughout pregnancy, where replacement therapy must be continued.

Who Must Not Use Thybon (Contraindications)

Thyroid hormone preparations are generally contraindicated in patients with:

  • Uncorrected Adrenal Cortical Insufficiency: Starting therapy before correcting adrenal deficiency can precipitate an acute adrenal crisis.
  • Untreated Thyrotoxicosis: An existing state of excessive thyroid hormone.
  • Acute Myocardial Infarction (MI) uncomplicated by hypothyroidism.
  • Known Hypersensitivity to liothyronine sodium or any of the inactive ingredients/excipients in the formulation.

Populations with Restrictions or Special Consideration

  • Treatment of Obesity/Weight Loss: Thybon is not recommended for the treatment of obesity or for weight loss, alone or with other agents, in patients with normal thyroid function (euthyroid patients).
  • Cardiovascular Disease: Use requires great caution in elderly patients or those with known or suspected cardiovascular disease (e.g., angina pectoris), due to the risk of aggravating cardiac conditions. These patients generally require lower starting doses.
  • Pregnancy and Lactation: Use is allowed during pregnancy, though dosage requirements may increase. It is also generally acceptable during breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Tibolone (Thybon) is defined by documented pharmacokinetic changes and specific co-administration restrictions detailed in regulatory sources.

Pharmacokinetic Interactions (Reduced Exposure)

Co-administration with medicines classified as strong metabolic enzyme inducers may result in a reduction in the plasma concentration of Tibolone and its active metabolites. This is due to an officially documented increased metabolic clearance. Specific interacting medicines that may reduce exposure include the antibiotic Rifampicin and enzyme-inducing antiepileptic drugs, such as Phenytoin, Carbamazepine, and Phenobarbitone. Additionally, the herbal product St John's Wort (Hypericum perforatum) is documented as an enzyme inducer that may lead to reduced Tibolone exposure.

Pharmacodynamic Interactions (Coagulation)

Tibolone may increase the anticoagulant activities of co-administered oral anticoagulants, including Warfarin. This documented pharmacodynamic interaction requires the mandatory monitoring of coagulation parameters, such as the International Normalized Ratio (INR), throughout the period of co-administration.

Formal Co-administration Restriction

The combination of Tibolone with any separate progestogen is a formally prohibited combination documented in official regulatory labels. This restriction is established based on the established hormonal profile of Tibolone.

Mechanism of Action

Selective Regulation via Active Metabolites

Tibolone functions as a prodrug, rapidly metabolizing into three distinct active components that engage a coordinated, tri-hormonal mechanism. These metabolites act as agonists at the Estrogen, Progesterone, and Androgen Receptors (ER, PR, AR), initiating signaling cascades that contribute to the modulation of key physiological systems.


Enzyme-Driven Tissue Selectivity

The mechanism is defined by its selectivity, achieved through the metabolites' ability to modulate local enzyme activity (specifically Sulfatase and 17beta-HSD) within target tissues. This interference controls the concentration of active estrogens, resulting in reduced estrogenic stimulation in tissues like the breast and inducing secretory differentiation in the endometrium via PR agonism.


Central and Skeletal Homeostasis Modulation

By activating Estrogen Receptors (ERs) in the hypothalamus, the mechanism re-stabilizes the brain's thermoregulatory set-point, resulting in the adjustment of peripheral vascular responses. Concurrently, the estrogenic metabolites act on bone cells to suppress osteoclast activity and influence the bone remodeling pathway, contributing to the regulation of bone turnover.

Dosage and Administration Information

How to Use Thybon: Official Administration Guidelines

Thybon (tibolone) is strictly for oral use and is supplied as a 2.5 mg tablet. The required administration method is a fixed daily dose of one tablet, which should be swallowed whole with water or another drink. This regimen is intended for continuous use, meaning the tablet is taken daily without interruption, and a separate progestogen must not be added to the treatment. Patients may take the medicine with or without food, but it should be taken once daily, preferably at the same time each day.

Treatment Initiation and Timing Rules

Standard guidelines specify that for treatment continuation, the lowest effective dose for the shortest duration should be used. There are specific time-relationship constraints for initiation: women experiencing a natural menopause must commence treatment at least 12 months after their final natural bleed. For women who have undergone surgical menopause, treatment may begin immediately.

Missed Dose Instructions

If a dose is missed, it should be taken as soon as the patient remembers, unless it is more than 12 hours overdue. If the 12-hour interval has been exceeded, the missed dose must be skipped entirely, and the next scheduled dose should be taken at the normal time; patients must not take two doses to compensate for the skipped one. Furthermore, administration rules specify that no dose adjustment is necessary for the elderly population.

Recent Clinical Evidence

Research evidence / Overview of studies for Thybon (Tibolone)


Evidence for Managing Vasomotor and Climacteric Symptoms

The research into Tibolone was studied for conditions characterized by fluctuating or episodic manifestations related to oestrogen deficiency, primarily consisting of short-term randomized controlled trials (RCTs). These trials were often placebo-controlled. Researchers focused on documenting the frequency and intensity of hot flashes and night sweats using patient diaries. Studies also examined patient-reported outcomes describing perceived discomfort linked to other climacteric symptoms.

Studies monitored how symptoms evolved in the observed populations, and reports described patterns observed in the studies regarding symptom frequency compared to the placebo group. Research highlights patient-reported outcomes describing perceived discomfort related to overall functioning.

However, long-term effects are not fully established for symptom relief. Most high-quality evidence focuses on short-term changes, and follow-up durations were limited in many primary trials. This means there is limited information for long-term outcomes past the intermediate-term (one to two years).


Evidence for Prevention of Bone Mineral Density (BMD) Loss

The evidence primarily stems from Intermediate-term RCTs that was studied for outcomes related to systemic or functional imbalance (bone density) alongside long-term trials that monitored major clinical outcomes like fractures. Researchers specifically monitored changes by measuring Bone Mineral Density (BMD) at key sites like the hip and spine. The long-term trials also examined the incidence of new fractures across the study period.

Studies report how symptoms evolved in the observed populations, and data show patterns related to BMD measurements where the measurements were observed in some studies to differ from the placebo group.

A key area of uncertainty relates to findings regarding long-term effects in older populations. While studies monitored outcomes related to physical discomfort, evidence quality varies across studies; specific findings from the long-term fracture studies have led to continued research scrutiny, highlighting that results apply only to the populations studied and need careful contextualization.

Key Studies & References

  1. Tibolone - LiverTox (NIH authoritative drug information)

Frequently Asked Questions (FAQ)

Common questions about Thybon (FAQ)


Q: Does Thybon contain T3 or T4, or both?

The active ingredient in Thybon is liothyronine sodium, which is the synthetic version of the thyroid hormone T3 (triiodothyronine). Official product information indicates that T3 is the more biologically active form of the thyroid hormone. The medicine does not contain T4 (levothyroxine).


Q: How is Thybon different from other thyroid hormone medicines?

Thybon's active ingredient, liothyronine, is a synthetic form of T3 (triiodothyronine). Regulatory information notes that T3's activity is observed more rapidly and its half-life is shorter compared to T4-only treatments.


Q: Are there any common foods or supplements that interact with Thybon?

Regulatory documents typically state that patients should maintain their normal diet unless given specific instruction. However, the product label documents interactions with certain substances, including herbal products and multivitamins that contain minerals.


Q: Is Thybon appropriate for children or adolescents?

The active ingredient, liothyronine, is used to treat hypothyroidism in the pediatric population. Official labeling confirms the medicine's indication for the pediatric population and notes that temporary hair loss is a potential side effect in children during the first few months of therapy.


Q: What is the difference between Thybon and natural desiccated thyroid preparations?

The active ingredient in Thybon is synthetic liothyronine (T3). In contrast, natural desiccated thyroid (NDT) preparations are derived from animal thyroid glands and naturally contain a combination of both T4 and T3 hormones.


Q: Are there specific symptoms that should prompt me to contact my healthcare provider while on Thybon?

Official safety information emphasizes seeking medical attention for symptoms such as chest pain or a rapid, irregular heartbeat or pulse, as these may be signs of serious complications.


Q: Does Thybon interact with supplements like iron or calcium?

Regulatory documents state that supplements containing minerals like iron or calcium may decrease the absorption and effects of liothyronine. Regulatory documents note that administration should typically be separated by at least four hours.


Q: Can Thybon cause temporary hair loss when first starting treatment?

Hair loss is noted as an adverse reaction in the official safety profile. This effect is sometimes described as transient (temporary) and has been reported in children during the first few months after starting treatment.


Q: What is the recommended maximum duration of Thybon treatment?

Official guidelines stress that for the treatment of climacteric symptoms, treatment should be for the shortest duration at the lowest effective dose. This duration is subject to a doctor's ongoing assessment of the individual's benefits and risks.


Q: How long does it typically take to see any effects from Thybon?

Official product information describes the active substance, liothyronine, as having a relatively rapid action. The effects are typically observed within a few hours to one day after administration.


Q: Does taking Thybon require regular blood tests?

Official guidelines state that taking Thybon requires regular follow-up visits with a healthcare provider. Blood tests, such as those monitoring TSH levels, are required for ongoing assessment of the body's response to the therapy.


Q: Does Thybon have any risk of withdrawal effects if stopped?

For the treatment of menopausal symptoms, a gradual reduction in the dose may be recommended when stopping the medicine. This practice is noted as an approach to help mitigate the return of menopausal symptoms.


Q: Why is Thybon sometimes prescribed when other thyroid medications don't seem to work?

T3-containing therapies, such as Thybon, have been used as an alternative treatment for a subgroup of patients with persistent symptoms while taking T4-only medication. Some research indicates that these patients may respond to or prefer the T3 regimen.


Q: Does Thybon interact with birth control pills?

Official product information indicates that oral contraceptives containing estrogen may interact with liothyronine sodium. Official product information notes that the thyroid dose may need to be assessed when used concurrently with these medicines.


Q: Is Thybon considered a lifetime medication?

For the management of hypothyroidism, regulatory-aligned information indicates that treatment may be required for the rest of a patient's life to control symptoms. Patients are generally advised that the therapy should be continued as prescribed.


Q: Can Thybon cause anxiety or mood changes?

Regulatory documents list nervousness, anxiety, and irritability as documented adverse reactions for the active ingredient, liothyronine. These effects are often associated with symptoms of overdosage.


Q: Does my diet need to change while taking Thybon?

Unless specific instructions are provided by a doctor, patients should continue their normal diet. However, it is documented that the timing of administration relative to food or certain supplements may affect the drug's absorption.


Q: What are the signs of taking too much Thybon?

Official regulatory documents state that signs of taking too much Thybon are often related to hyperthyroidism or overdosage. These symptoms can include a fast or irregular heartbeat, tremors, headache, excessive sweating, and insomnia.


Q: Is Thybon safe for people with diabetes?

Official information indicates that using thyroid hormone therapy, such as Thybon, may worsen blood sugar control in patients with diabetes mellitus. Patients with diabetes mellitus are advised that careful monitoring of blood glucose levels may be required when starting or changing the dose.


Q: Can Thybon affect sleep patterns?

Regulatory documents list insomnia (trouble sleeping) as a documented adverse reaction of liothyronine sodium. This effect is sometimes associated with higher doses or may be a symptom of potential overdosage.


Q: Does Thybon have an official black box warning?

Liothyronine carries an FDA Boxed Warning (the agency's strongest safety caution). This Boxed Warning specifies that the medication is not indicated for treating obesity or weight loss in patients with normal thyroid function.


Q: What is Thybon's effect on cholesterol levels?

Studies on the active substance, tibolone, have documented effects on lipid profiles, including statistically significant decreases in HDL cholesterol (often called 'good' cholesterol). Generally, no significant changes are reported for LDL cholesterol or triglycerides.


Q: What is the typical half-life of Thybon in the body?

Liothyronine (the active substance) has a short biological half-life in the body, which is typically reported to be around 2.5 days. This is shorter than the half-life of T4-only thyroid medications.


Q: Does Thybon have known interactions with alcohol?

Official information does not list a formal contraindication for alcohol use, but documented side effects like nervousness or headache may be exacerbated by alcohol consumption.


Q: Do studies support the use of Thybon over T4-only treatment for certain patients?

While major differences were not found in overall quality of life measures, some research indicates that a subgroup of patients with persistent symptoms on T4-only treatment may respond to or prefer the T3 regimen. Some research has suggested potential improvements in quality of life and memory function for certain symptomatic patient groups.


Q: Can Thybon impact fertility?

Official safety information for liothyronine lists impaired fertility as a potential adverse reaction.

How should Thybon be stored and disposed of?

How to Store and Dispose of Thybon?

The official regulatory labeling for Thybon (Tibolone) tablets specifies strict storage and disposal requirements to maintain product stability and safety.


Required Storage Conditions

Item Requirement
Temperature Store below 30°C (do not exceed 30 C).
Protection Must be kept protected from light and moisture.
Packaging Keep tablets in the original package and outer carton until use.

Handling and Disposal

Item Requirement
Child Safety Keep this medicine out of the sight and reach of children.
Expiry Do not use the medicine after the expiry date printed on the carton.
Disposal Do not dispose of Thybon via wastewater or household waste. Consult a pharmacist for instructions on how to properly discard unused or expired product according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Thybon found in:

A-Z Index: